Imported drugs take the initiative to reduce prices to grab the market in the future or more drugs "self-de-price"

Incoming drugs actively reduce prices to grab the market more than
imported drugs actively apply to reduce the supply price of future or more drugs "self-de-price"
days ago, beijing Pharmaceutical Centralized Procurement Service Center issued a notice that Pfizer and Xi'an Yangsen and other pharmaceutical companies have voluntarily applied to reduce the price of some drugs supply, involving 21 kinds of drugs.
analysis said that the positive influx of imported drugs, local innovative drugs and generic drugs are also competing for the market, the future of the "close to the flesh" war will not be less, so it can be expected that more and more original prices do not want to loosen the drug companies will offer to take the initiative to reduce prices.
in the past, "high down" pharmaceutical companies have begun to lower the body, the initiative to reduce prices. Recently, the Beijing Pharmaceutical Centralized Purchasing Service Center issued "on Pfizer and Xi'an Yangsen and other companies some of the drug active price reduction notice", showing that Pfizer and Xi'an Yangsen and other pharmaceutical companies have been through the drug sunshine procurement of independent price reduction function, the initiative to apply to reduce the price of some drugs supply, involving 21 kinds of drugs.Pharmaceutical companies in China to meet the "active price reduction tide
this time appeared in Beijing's active price reduction list, including the United States, France, Germany, Australia, Spain, Italy, the Netherlands and other countries produced imported drugs, specific dosage forms covering capsules, tablets, injections and other categories.
Recently, Hubei Province also issued a "announcement on lowering the price of Pfizer's imported products", saying that Pfizer Investment Co., Ltd. has voluntarily applied to reduce the number of injections including yew alcohol, acetinoid tablets, injections with agarose, injections with recombinant human coagulation factors IX and other imported products online prices, a total of 20 kinds of drugs, the reduction of 3.4% to 10.2%, it is understood that it will be completed by July 15 price adjustment and price adjustment drug return and exchange work.
Also in this month, Gansu Province issued a notice that Xi'an Yangsen Pharmaceutical Co., Ltd. and other initiatives to apply for the product online price adjustment, including Xi'an Yangsen's Daxi (injection land West Talbin freeze-dried powder needle, 50mg) from the original 10327.22 yuan to 4996 yuan, a drop of up to 51.6%! It is understood that the drug is known as the bone marrow growth abnormal patients life-saving drugs.
Take Pfizer, the global pharmaceutical giant, which has cut prices in China to include both original drugs that have passed the patent protection period, patented drugs that have been in the protection period, and even targeted new drugs that have been on the market in recent years. In addition to the price reduction, Pfizer continues to deeply cultivate the Chinese market, the recent support of china's breast cancer all-round cycle management conference stressed that cancer treatment should be included in the management of chronic diseases.and local medicine will be "close to the flesh
from the past independent pricing, high prices, to be willing to accept negotiations but individual change of heart to withdraw, and now more and more imported drugs offered to reduce prices, in the eyes of the industry, imported drugs pricing strategy in China 180 degrees change, all because of China's relevant policies and markets in recent years have changed dramatically.
industry analysts believe that the initiative to reduce prices is a lot of foreign pharmaceutical companies in China after the performance of pressure to take the "throw stone to ask the way" action. "On the one hand, imported drugs in China gradually lost 'super-national treatment', and sooner or later will face the problem of patent expiration, when the domestic generic drugs up, hit the market is likely to be rapidly lost; its represents.
From May 1 this year, China has implemented zero tariffs on imports of anti-cancer drugs, including all common drugs, alkaloid drugs with anti-cancer effects, etc., and the executive meeting of the State Council in June also identified measures to speed up the approval of new drugs already listed overseas, promote the accelerated price reduction of anti-cancer drugs, and strengthen the guarantee of the supply of shortage drugs.
"Although China gives the green light to imported drugs in terms of taxes, approvals, etc., this does not mean that local competition will weaken." "In the eyes of the industry, precisely because of the positive influx of imported drugs, local innovative drugs and generic drugs are also competing for the market, the future of the "close to the flesh" war will not be less, so it can be foreseen that more and more original prices do not want to loosen the pharmaceutical companies will offer to take the initiative to reduce prices. (Guangzhou Daily)